Jeffrey Aronin is the founder and CEO of Paragon Biosciences. He lives to create and invest in companies that search for and develop effective treatments for rare and under-treated conditions. He’s been pursuing that dream for 20 years. Aronin possesses finely-honed skills in the areas of finance, marketing, and business development.
Jeffrey Aronin has been recognized for the value of his work, including the Frederic A. Gibbs Discovery Award and the 2017 Weizmann Leadership Award. The Illinois Holocaust Museum & Education Center honored Aronin with its 2010 Humanitarian Award. Recently, Life Sciences Pennsylvania honored Aronin with its 2017 Deal of the Year Award.
Paragon Biosciences invests in and incubates companies devoted to finding pharmaceutical therapies and cures for diseases for which there are few to no treatment options available. The FDA approved 13 new medications developed under the Paragon Biosciences umbrella in just the last decade. That’s a level of performance that even some leading pharmaceutical companies can’t claim.
Paragon Biosciences follows a three-step process to create new drugs.
- First they identify a disease that for which there are few or no treatments. Then they find out how many people suffer from that disease. Then they determine the availability of existing treatments.
- Next, they build the companies that will work to create the drugs that will treat the disease.
- Finally, they develop the new medicines. Developing a new medicine takes time and money, and Paragon provides the resources that allow those companies to conduct the research and spend the time necessary to bring a new treatment to market.
Among the companies that Jeffrey Aronin and Paragon Biosciences have created are Castle Creek and Harmony Biosciences. Castle Creek operates under Paragon’s umbrella and strives to develop new treatments for patients with severe dermatologic conditions. Castle Creek has several products that are nearing completion. Harmony Biosciences is a pharmaceutical company that is working to develop new drugs that will address the unmet needs of patients with problems affecting their sleep and disorders of the central nervous system.